MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Balance Sheets Overview

Current Ratio
82.15%
Quick Ratio
82.15%
Cash Ratio
75.47%
Unit: Thousand (K) dollars
Assets Breakdown
    • Other investment
    • Cash and cash equivalents
    • Prepaid expenses
    • Others
Liabilities Breakdown
    • Paid-in capital
    • Accumulated deficit
    • Accounts payable
    • Others
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
1,391
2,823
3,240
4,568
Accounts receivable
0
0
1,000
100
Prepaid expenses
112
255
384
386
Other current assets
11
11
11
11
Total current assets
1,514
3,089
4,635
5,065
Property, plant and equipment, net
66
66
-
-
Other investment
5,350
5,350
5,350
5,350
Total assets
6,930
8,505
9,985
10,415
Accounts payable
1,597
457
508
480
Accrued research and development costs
26
148
198
46
Accrued expenses and other current liabilities
220
1,109
194
351
Total current liabilities
1,843
1,714
900
877
Preferred stock, no par value, 100,000,000 shares authorized and 351,037 shares of series a convertible preferred stock issued and outstanding at june 30, 2026 and december 31, 2025
0
0
0
0
Common stock, no par value, 400,000,000 shares authorized at june 30, 2026 and december 31, 2025 4,330,314 and 3,925,314 shares issued at june 30, 2026 and december 31, 2025, respectively 4,256,284 and 3,821,236 shares outstanding at june 30, 2026 and december 31, 2025, respectively
0
0
0
0
Paid-in capital
281,039
280,988
280,105
279,759
Accumulated deficit
-275,952
-274,197
-271,020
-270,221
Total stockholders' equity
5,087
6,791
9,085
9,538
Total liabilities and stockholders' equity
6,930
8,505
9,985
10,415
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Cash and cashequivalents$1,391K (-53.73%↓ Y/Y)Prepaid expenses$112K (-75.76%↓ Y/Y)Other current assets$11K (-59.26%↓ Y/Y)Other investment$5,350K (0.00%↑ Y/Y)Total current assets$1,514K (-62.34%↓ Y/Y)Property, plant andequipment, net$66K Total assets$6,930K (-26.04%↓ Y/Y)Total liabilities andstockholders' equity$6,930K (-26.04%↓ Y/Y)Total stockholders'equity$5,087K (-40.64%↓ Y/Y)Total currentliabilities$1,843K (130.38%↑ Y/Y)Accumulated deficit-$275,952K (-2.49%↓ Y/Y)Paid-in capital$281,039K (1.16%↑ Y/Y)Accounts payable$1,597K (245.67%↑ Y/Y)Accrued expenses andother current...$220K (-17.29%↓ Y/Y)Accrued research anddevelopment costs$26K (-63.89%↓ Y/Y)

Cyclerion Therapeutics, Inc. (CYCN)

Cyclerion Therapeutics, Inc. (CYCN)